CalciMedica, Inc.

CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

Auxora Phase 1b proof-of-concept data in pulmonary hypertension (PH) and CM5480 IND submission both anticipated in mid-2027